

## 2023 HematoLogics, Inc Staff Publications

MR Loken

A Menssen

D Xu

D Wells

L Lott

R. Bennington

L Pardo

C Hudson

W Fritschle

FC Hsu

A Eckel

J Perry

L Hartmann

N Zaidi

F Dai

J Cook

A Nalla

B Burnworth

van der Velden, V. H. J., Preijers, F., Johansson, U., Westers, T. M., Dunlop, A., Porwit, A., Béné, M. C., Valent, P., te Marvelde, J., Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., **Loken, M. R.**, Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., **Wells, D. A.**, Della Porta, M. G., Burbury, K., Bellos, F., Weiß, E., Kern, W., & van de Loosdrecht, A. (2023). Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet. *Cytometry Part B: Clinical Cytometry*, 104(1), 15–26.

van de Loosdrecht, A. A., Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W., Preijers, F., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Johansson, U., **Loken, M. R.**, ... Ireland, R. (2023). Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group. *Cytometry Part B: Clinical Cytometry*, 104(1), 77–86.

Cutler, J. A., Pugsley, H. R., **Bennington, R.**, **Fritschle, W.**, **Hartmann, L.**, **Zaidi, N.**, **Menssen, A. J.**, Singleton, T. P., **Xu, D.**, **Loken, M. R.**, **Wells, D. A.**, Brodersen, L. E., & Zehentner, B. K. (2023). Integrated analysis of genotype and phenotype reveals clonal evolution and cytogenetically driven disruption of myeloid cell maturation in myelodysplastic syndromes. *Cytometry Part B: Clinical Cytometry*, 104(2), 183–194.

**Hsu, F.-C.**, **Hudson, C.**, Wilson, E. R., **Pardo, L. M.**, Singleton, T. P., **Xu, D.**, Zehentner, B. K., Hitzler, J., Berman, J., **Wells, D. A.**, **Loken, M. R.**, & Brodersen, L. E. (2023). The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease. *Cytometry Part B: Clinical Cytometry*, 104(4), 311–318.

Danielle C. Kirkey, Anisha M. Loeb, Sommer Castro, Cyd Nourigat McKay, LaKeisha Perkins, **Laura Pardo**, Amanda R. Leonti, Thao T. Tang, **Michael R. Loken**, Lisa Eidenschink Brodersen, Keith R. Loeb, David A. Scheinberg, Quy Le, Soheil Meshinchi; Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia. *Blood Adv* 2023; 7 (7): 1178–1189.

Quy Le, Thao Tang, Amanda Leonti, Sommer Castro, Cyd Nourigat McKay, LaKeisha Perkins, **Laura Pardo**, Danielle Kirkey, Tiffany Hylkema, Lindsey Call, Makia Manselle, Cristina Abrahams, Kristin Bedard, Arturo Molina, Lisa Eidenshink Brodersen, **Michael R. Loken**, Katherine Tarlock, Soheil Meshinchi, Keith R. Loeb; Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia. *Blood Adv* 2023; 7 (9): 1666–1670.

Koehne, Guenther; Tomlinson, Benjamin; Suh, Hyung; Koura, Divya; Cho, Christina<sup>3</sup>; Bambace, Nadia M; Bernard, Léa<sup>6</sup>; Shah, Nirali N; Walter, Roland; Dipersio, Joh<sup>9</sup>; Perales, Miguel-Angel; **Loken, Michael R**; Breitschwerdt, Kyle; Nath, Sritama; Raffel, Glen; Cooper, Brenda W. P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS. *HemaSphere* 7(S3):p e24418bc, August 2023.

Bertrums EJM, Smith JL, Harmon L, Ries RE, Wang YJ, Alonzo TA, **Menssen AJ**, Chisholm KM, Leonti AR, Tarlock K, Ostronoff F, Pogossova-Agadjanyan EL, Kaspers GJL, Hasle H, Dworzak M, Walter C, Muhlegger N, Morerio C, Pardo L, Hirsch B, Raimondi S, Cooper TM, Aplenc R, Gamis AS, Kolb EA, Farrar JE, Stirewalt D, Ma X, Shaw TI, Furlan SN, Brodersen LE, **Loken MR**, Van den Heuvel-Eibrink MM, Zwaan CM, Triche TJ, Goemans BF, Meshinchi S. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. *Haematologica*. 2023 Aug 1;108(8):2044-2058. doi: 10.3324/haematol.2022.281653. PMID: 36815378; PMCID: PMC10388277.

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, **Michael R. Loken**, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne, Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT), *Blood*, Volume 142, Supplement 1, 2023, Page 483, ISSN 0006-4971

**Jacqueline A. Cook, Loren Lott, Jenna Perry, Arun Nalla, Dongbin Xu, Chad A. Hudson, Denise A. Wells, Michael R. Loken, Andrew J. Menssen**, Residual Mast Cells Can Explain Persistent Molecular Positivity in Difference from Normal Flow Cytometric-Defined MRD Negative Core Binding Factor AML, *Blood*, Volume 142, Supplement 1, 2023, Page 426, ISSN 0006-4971

Lambo, S., Trinh, D.L., Ries, R.E., Jin, D., Setiadi, A., Ng, M., Leblanc, V.G., **Loken, M.R.**, Brodersen, L.E., **Dai, F.** and **Pardo, L.M.**, 2023. A longitudinal single-cell atlas of treatment response in pediatric AML. *Cancer Cell*, 41(12), pp.2117-2135.

Jessica A. Pollard, MD; Erin Guest, MD; Todd A. Alonzo, PhD; Robert B. Gerbing, MS; **Mike R. Loken**, PhD; Lisa Eidenschink Brodersen, PhD; E. Anders Kolb, MD; Richard Aplenc, MD, PhD; Soheil Meshinchi, MD, PhD; Susana C. Raimondi, PhD; Betsy Hirsch, PhD; and Alan S. Gamis, MD, 2023. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531, *Journal of Clinical Oncology*, Volume 39, Issue 29, 3149-3160.

Danielle C Kirkey, Melia Blankenfeld, Tiffany Hylkema, Deryk Loo, Ashley Ward, Leila Robinson, Jack H Peplinski, Logan K Wallace, **Laura Pardo, Andrew J. Menssen**, Rhonda E Ries, Soheil Meshinchi, CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate, *Blood*, Volume 142, Supplement 1, 2023, Page 5958, ISSN 0006-4971

Danielle Kirkey, Leila Robinson, Tiffany Hylkema, Anisha Loeb, Sommer Castro, Thao Tang, Rhonda E Ries, Cyd McKay, Christina Root, **Laura Pardo**, Keith Loeb, Quy Le, Soheil Meshinchi. Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML.DOI: 10.1200/JCO.2023.41.16\_suppl.2553 *Journal of Clinical Oncology* 41, no. 16\_suppl (June 01, 2023) 2553-2553.

Monique Chavez, Sridhar N Srivatsan, Christopher A Miller, **Andrew J. Menssen**, Ajay Khanna, Jin Shao, Catrina Fronick, Robert Fulton, Sharon E Heath, Constantine Logothetis, Tasha Burton, Victoria Donaldson, Claudia Cabrera, Raya Saba, Kiran R. Vij, Eric J. Duncavage, Meagan Jacoby, Matthew J. Walter, Reduced Subclone Diversity in Clonal Cytopenia of Undetermined Significance Compared to Myelodysplastic Syndrome, *Blood*, Volume 142, Supplement 1, 2023, Page 2696, ISSN 0006-4971.

Edoardo Pennesi, Erica Brivio, Marieke E Willemse, Yilin Jiang, Vincent HJ van der Velden, H Berna Beverloo, **Chad Hudson**, Nyla A Heerema, Luke Kuttschreuter, Jamie Frediani, Susan Spiller, Sandeep Batra, Michele Redell, Nicoletta Bertorello, Franco Locatelli, Inge M van der Sluis, Michael Roth, Nobuko Hijjiya, C Michel Zwaan. Preliminary results from the first-in-child phase II trial (ITCC-054/COG-

AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML). DOI: 10.1200/JCO.2023.41.16\_suppl.10017 Journal of Clinical Oncology 41, no. 16\_suppl (June 01, 2023) 10017-10017.

Brivio, E., Pennesi, E., Willemse, M., Jiang, Y., van der Velden, V., Beverloo, B., **Hudson, C.**, Kuttchreuter, L., van der Sluis, I., Brethon, B. and Bautista, F., 2023. P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA. HemaSphere, 7(Suppl).

Brivio, E., Pennesi, E., Willemse, M.E., Huitema, A.D., Jiang, Y., van Tinteren, H.D., van der Velden, V.H., Beverloo, B.H., den Boer, M.L., Rammeloo, L.A. and **Hudson, C.**, Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, p.JCO2300897.

Larsen, S.E., Erasmus, J.H., Reese, V.A., Pecor, T., Archer, J., Kandahar, A., **Hsu, F.C.**, Nicholes, K., Reed, S.G., Baldwin, S.L. and Coler, R.N., 2023. An RNA-based vaccine platform for use against mycobacterium tuberculosis. Vaccines, 11(1), p.130.

Dong Q, Wang Y, Xiu Y, Sakr H, **Burnworth B, Xu D**, O'Brien T, Burke J, Hu S, Zeng G, Zhao C. Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma. Br J Haematol. 2023 Mar;200(5):660-664. doi: 10.1111/bjh.18565. Epub 2022 Nov 14. PMID: 36375473; PMCID: PMC10162861.

Huang, J.J., Appelbaum, J.S., Russell, K., Shaw, C., **Eckel, A.M.**, Chen, X., Vyas, R.D., Hendrie, P.C., Halpern, A.B., Mawad, R. and Cassaday, R.D., 2023. Treatment Outcomes for Adults with Mixed Phenotypic Acute Leukemia: A Large Single-Center Retrospective Study. Blood, 142, p.2838.